Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Richard Daniell Sells 25,000 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) EVP Richard Daniell sold 25,000 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $2,392,447.05. This represents a 30.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard Daniell also recently made the following trade(s):

  • On Wednesday, November 11th, Richard Daniell sold 20,003 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $42.80, for a total value of $856,128.40.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.28 during mid-day trading on Thursday, hitting $43.52. 9,218,408 shares of the stock were exchanged, compared to its average volume of 6,859,138. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The business has a fifty day moving average price of $39.88 and a 200 day moving average price of $34.96. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $44.31. The stock has a market capitalization of $50.72 billion, a price-to-earnings ratio of 101.22, a PEG ratio of 3.97 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion during the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.78 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, September 4th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $48.15.

View Our Latest Analysis on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries News Roundup

Investors following TEVA have been watching these news items:

  • Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
  • Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
  • Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of TEVA. First Trust Advisors LP raised its stake in shares of Teva Pharmaceutical Industries by 693.7% during the third quarter. First Trust Advisors LP now owns 84,589 shares of the company’s stock valued at $3,350,000 after acquiring an additional 73,932 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $1,175,000. Edmond DE Rothschild Holding S.A. purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $1,648,000. USS Investment Management Ltd purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $10,840,000. Finally, WealthTrust Axiom LLC bought a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $279,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Further Reading

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.